GFC

GFC (Growth Factor Concentrate) is an advanced evolution of PRP that uses a specialized closed-system proprietary kit to extract, concentrate, and activate a higher-purity growth factor fraction from your blood. Unlike standard PRP (which contains the entire platelet fraction including cells, red blood cell contamination, and inflammatory cytokines), GFC uses leukocyte-poor processing to eliminate pro-inflammatory white blood cells and concentrate only the purified growth factors — including PDGF-BB, TGF-β1, VEGF, EGF, and bFGF — at significantly higher concentrations than conventional PRP. This results in a purer, more potent, and less inflammatory injectate that is clinically reported to produce superior hair density improvements with less post-injection discomfort.

A standard GFC protocol involves drawing 16 to 32 mL of blood into specialized GFC tubes containing a patented activator-free concentration medium. The tubes are centrifuged in a calibrated two-step process at specific g-forces and temperatures to separate red blood cells, white blood cells, and plasma fractions, concentrating the pure growth factor supernatant. The resulting GFC is a clear to pale-yellow, cell-free fluid injected into the scalp dermis using a fine 30-gauge needle via mesotherapy injection pattern. Topical anaesthetic cream (EMLA) applied 45 minutes before the procedure, combined with scalp nerve block injections, makes the procedure well-tolerated with minimal discomfort.

Emerging clinical evidence from comparative studies suggests GFC demonstrates superior or comparable efficacy to activated PRP for androgenetic alopecia, with reported advantages including: higher growth factor concentrations per mL of injectate, lower inflammatory response post-injection (less redness and tenderness), better patient comfort, and no requirement for exogenous calcium chloride activation (the purification process inherently activates growth factor release). However, both GFC and high-quality PRP — when prepared with validated concentration protocols — demonstrate clinically meaningful improvements in hair density and caliber. Individual response varies based on hair loss stage, genetics, and concurrent medical therapy.

The standard GFC treatment protocol consists of 3 to 4 monthly sessions for the initial induction phase. Results in terms of increased hair density, reduced shedding, and improved hair caliber are typically measurable by trichoscopy at 3 to 4 months. Maintenance therapy with 2 to 3 sessions annually is recommended to sustain growth factor stimulation, as androgenetic alopecia is a progressive, genetically driven condition that will continue to miniaturize remaining susceptible follicles if biological support is withdrawn. Concurrent finasteride (1 mg daily in males) or dutasteride, and topical minoxidil, synergistically enhance and prolong GFC results.

Yes — GFC is highly synergistic with hair transplantation and medical therapy. When used peri-operatively around a hair transplant, GFC activates the quiescent scalp microenvironment, improves graft take rates, and accelerates new follicle vascularization in the recipient zone. It is commonly incorporated as: an intra-operative scalp injection immediately after recipient site creation; a post-operative protocol starting 6 to 8 weeks after transplant for 3 monthly sessions; and a long-term bi-annual maintenance to protect native hair. GFC can be combined with laser low-level light therapy (LLLT), topical minoxidil, and oral finasteride as part of a comprehensive, evidence-based hair loss management programme.